Ian M Silverman
Overview
Explore the profile of Ian M Silverman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
944
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fontana E, Rosen E, Lee E, Hojgaard M, Mettu N, Lheureux S, et al.
J Natl Cancer Inst
. 2024 May;
116(9):1439-1449.
PMID: 38710487
Background: Camonsertib is a selective oral inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase with demonstrated efficacy in tumors with DNA damage response gene deficiencies. On-target anemia is the main...
2.
Pelster M, Silverman I, Schonhoft J, Johnson A, Selenica P, Ulanet D, et al.
NPJ Precis Oncol
. 2024 Apr;
8(1):82.
PMID: 38561473
Pancreatic acinar cell carcinoma (PACC) is a rare form of pancreatic cancer that commonly harbors targetable alterations, including activating fusions in the MAPK pathway and loss-of-function (LOF) alterations in DNA...
3.
Nakazawa M, Silverman I, Rimkunas V, Veloso A, Glodzik D, Johnson A, et al.
Mol Cancer Ther
. 2024 Apr;
23(7):1057-1065.
PMID: 38561019
Targeting the DNA damage response (DDR) pathway is an emerging therapeutic approach for leiomyosarcoma (LMS), and loss of RNase H2, a DDR pathway member, is a potentially actionable alteration for...
4.
Yap T, Fontana E, Lee E, Spigel D, Hojgaard M, Lheureux S, et al.
Nat Med
. 2023 Jun;
29(6):1400-1411.
PMID: 37277454
Predictive biomarkers of response are essential to effectively guide targeted cancer treatment. Ataxia telangiectasia and Rad3-related kinase inhibitors (ATRi) have been shown to be synthetic lethal with loss of function...
5.
Glodzik D, Selenica P, Rogge R, Silverman I, Mandelker D, Harris S, et al.
J Mol Diagn
. 2023 Mar;
25(5):295-310.
PMID: 36944408
Patient selection for synthetic lethal-based cancer therapy may be improved by assessment of gene-specific loss of heterozygosity (LOH) and biallelic loss of function (LOF). This report describes SyNthetic lethal Interactions...
6.
Zingg D, Bhin J, Yemelyanenko J, Kas S, Rolfs F, Lutz C, et al.
Nature
. 2022 Sep;
609(7929):E13.
PMID: 36050473
No abstract available.
7.
Zingg D, Bhin J, Yemelyanenko J, Kas S, Rolfs F, Lutz C, et al.
Nature
. 2022 Aug;
608(7923):609-617.
PMID: 35948633
Somatic hotspot mutations and structural amplifications and fusions that affect fibroblast growth factor receptor 2 (encoded by FGFR2) occur in multiple types of cancer. However, clinical responses to FGFR inhibitors...
8.
Silverman I, Li M, Murugesan K, Krook M, Javle M, Kelley R, et al.
J Mol Diagn
. 2022 Feb;
24(4):351-364.
PMID: 35176488
Cholangiocarcinoma (CCA) is a heterogeneous biliary tract cancer with a poor prognosis. Approximately 30% to 50% of patients harbor actionable alterations, including FGFR2 rearrangements. Pemigatinib, a potent, selective fibroblast growth...
9.
Duell J, Obr A, Augustin M, Endell J, Liu H, Geiger S, et al.
Leuk Lymphoma
. 2021 Nov;
63(2):468-472.
PMID: 34779360
No abstract available.
10.
Shan M, Ji X, Janssen K, Silverman I, Humenik J, Garcia B, et al.
Life Sci Alliance
. 2021 Jul;
4(9).
PMID: 34315813
Two features of eukaryotic RNA molecules that regulate their post-transcriptional fates are RNA secondary structure and RNA-binding protein (RBP) interaction sites. However, a comprehensive global overview of the dynamic nature...